An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203
Condition: Sporadic Inclusion Body MyositisInterventions: Drug: Bimagrumab; Drug: PlaceboSponsor: Novartis PharmaceuticalsNot yet recruiting - verified October 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials